bpc-157 adverse effects humans case report The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity The Hidden Risks of BPC‑157:
Description
Lactic acid bacteria have been investigated as a suitable means of delivering therapeutic proteins or peptides to mucosal surfaces in the body
Standard clinical dosing starts at 2.5 mg once weekly, increasing to 5 mg after 4 weeks, with further 2.5 mg increments every 4 weeks as needed
This makes it particularly effective for individuals suffering from chronic joint pain, arthritis , or sports-related ligament injuries like sprains or strains
Gastrin Gastrin is released by G-cells in the stomach and is a major stimulus for gastric acid secretion (30)
